Scopus
SJR Q1
Combined androgen blockade for advanced prostatic carcinoma
Prostate Cancer and Prostatic Diseases · Ocak 1999
Özet
Hormonal therapy has been mainstay of treatment for advanced forms of prostate cancer for over 50 y. The choice of hormonal therapy for carcinoma of the prostate depends not only on the desired progression-free and overall survival but also on the patient's quality of life, treatment costs and treatment toxicities. At the present time, several important questions have been raised over optimal treatment modalities for advanced prostate cancer. The optimal form of this therapy is still an enigma.
Makale Bilgileri
Toplam Atıf
12 atıf
· Scopus
ISSN13657852
Yayın TarihiOcak 1999
Cilt / Sayfa2 · 172-179
Scopus ID2-s2.0-0033401227
Kurumlar
University of Colorado Anschutz Medical Campus
Aurora United States
Havuzumuzdaki Atıflar 0
Bu makaleye, sistemimizdeki Scopus veritabanında bulunan 0 makale atıf yapmıştır. Scopus genel atıf sayısı: 12.
Bu makaleye, kendi Scopus havuzumuzdaki başka bir makaleden atıf kaydı bulunmuyor.
Scimago Dergi (ISSN Eşleşmesi)
Prostate Cancer and Prostatic Diseases
Q1
SJR Skoru2,025
H-Index85
YayıncıSpringer Nature
ÜlkeUnited Kingdom
Cancer Research (Q1)
Oncology (Q1)
Urology (Q1)
Metrikler
12
Atıf